Open Access Research Article Molecular, Cellular and Physiological Characterization of the Cancer Cachexia-inducing C26 Colon Carcinoma in Mouse
暂无分享,去创建一个
A. Baldi | F. Padula | E. Berardi | V. Cardillo | Paola Aulino | S. Adamo | D. Coletti | E. Spugnini | E. Rizzuto | B. Perniconi | Carla Ramina | Fabio Faiola
[1] Jeffrey S. Damrauer,et al. Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia , 2018, European journal of translational myology.
[2] T. Nagykálnai,et al. [Cachexia in cancer patients]. , 2016, Magyar onkologia.
[3] H. Kern,et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. , 2010, Autoimmunity reviews.
[4] W. Evans,et al. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. , 2010, The American journal of clinical nutrition.
[5] S. Merigliano,et al. Subclinical myopathy in patients affected with newly diagnosed colorectal cancer at clinical onset of disease: evidence from skeletal muscle biopsies , 2010, Neurological research.
[6] S. Gygi,et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation , 2009, The Journal of cell biology.
[7] A. Pristerá,et al. Modulation of Caspase Activity Regulates Skeletal Muscle Regeneration and Function in Response to Vasopressin and Tumor Necrosis Factor , 2009, PloS one.
[8] D. Birnbaum,et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism , 2009, British Journal of Cancer.
[9] A. Valencia,et al. From cancer genomes to cancer models: bridging the gaps , 2009, EMBO reports.
[10] J. Magyar,et al. Orally Available Selective Melanocortin-4 Receptor Antagonists Stimulate Food Intake and Reduce Cancer-Induced Cachexia in Mice , 2009, PloS one.
[11] J. Argilés,et al. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice , 2009, British Journal of Cancer.
[12] M. Taketo,et al. Mouse models of colon cancer. , 2009, Gastroenterology.
[13] P. Ponikowski,et al. Cachexia: a new definition. , 2008, Clinical nutrition.
[14] P. Vos,et al. Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia , 2008, British Journal of Cancer.
[15] Charles Giardina,et al. Mouse models for the study of colon carcinogenesis. , 2008, Carcinogenesis.
[16] Zhuangzhi Wang,et al. A Novel Role for CD4+ T Cells in the Control of Cachexia1 , 2008, The Journal of Immunology.
[17] A. Musarò,et al. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. , 2008, Human gene therapy.
[18] A. Musarò,et al. Measuring Mechanical Properties, Including Isotonic Fatigue, of Fast and Slow MLC/mIgf-1 Transgenic Skeletal Muscle , 2008, Annals of Biomedical Engineering.
[19] Zhen Lu,et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down‐regulated in human ovarian cancers by loss of heterozygosity and promoter methylation , 2008, Cancer.
[20] A. Pristerá,et al. Tumor Necrosis Factor‐α Inhibition of Skeletal Muscle Regeneration Is Mediated by a Caspase‐Dependent Stem Cell Response , 2008, Stem cells.
[21] F. Padula,et al. Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice , 2008, Neurological research.
[22] A. Goldberg,et al. FoxO3 controls autophagy in skeletal muscle in vivo. , 2007, Cell metabolism.
[23] K. Pienta,et al. The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy , 2007, CA: a cancer journal for clinicians.
[24] T. Rando,et al. High Incidence of Non-Random Template Strand Segregation and Asymmetric Fate Determination In Dividing Stem Cells and their Progeny , 2007, PLoS biology.
[25] D. Sassoon,et al. Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. , 2006, Genes & development.
[26] M. Grounds,et al. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx mice , 2006, Neuromuscular Disorders.
[27] Justin M. Hicks,et al. Text similarity: an alternative way to search MEDLINE , 2006, Bioinform..
[28] N. Kaminski,et al. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. , 2006, Cancer research.
[29] J. Encke,et al. An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo , 2006, Journal of Gastrointestinal Surgery.
[30] Laurens G. van der Flier,et al. Mass‐dependent decline of skeletal muscle function in cancer cachexia , 2006, Muscle & nerve.
[31] I. B. Borel Rinkes,et al. Synergistic Effect of Interstitial Laser Coagulation and Doxorubicin in a Murine Tumor Recurrence Model of Solitary Colorectal Liver Metastasis , 2006, Annals of Surgical Oncology.
[32] R. Schiffelers,et al. Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer , 2006, Journal of liposome research.
[33] J. Dipalma,et al. U.S. practices for colon cancer screening. , 2005, The Keio journal of medicine.
[34] Swarnali Acharyya,et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. , 2005, Cancer cell.
[35] J. Sebolt-Leopold,et al. A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. , 2005, Neoplasia.
[36] Jeffrey S. Damrauer,et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. , 2004, The Journal of clinical investigation.
[37] D. McCarthy,et al. Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. , 2004, Research in nursing & health.
[38] Y. Koyanagi,et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT , 2004, Cancer Gene Therapy.
[39] A. Carè,et al. Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis , 2004, Cancer Immunology, Immunotherapy.
[40] Maria Laura Belladonna,et al. Potent Antitumor Activity of Interleukin-27 , 2004, Cancer Research.
[41] D. Wagener,et al. Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model , 2004, Journal of Cancer Research and Clinical Oncology.
[42] H. Yao,et al. Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma. , 2003, Chinese medical journal.
[43] G. Peters,et al. Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma , 2003, British Journal of Cancer.
[44] T. Sugimura,et al. Enhancement of colon carcinogenesis by prostaglandin E2 administration. , 2003, Carcinogenesis.
[45] H. Tanke,et al. Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. , 2002, Cancer genetics and cytogenetics.
[46] G. Diffee,et al. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. , 2002, American journal of physiology. Cell physiology.
[47] M. Tisdale,et al. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. , 2000, Cancer research.
[48] L. Ding,et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. , 1999, Cancer research.
[49] H. Ishitsuka,et al. Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma , 1999, British Journal of Cancer.
[50] M. Monden,et al. Anti‐interleukin‐6 receptor antibody prevents muscle atrophy in colon‐26 adenocarcinoma‐bearing mice with modulation of lysosomal and ATP‐ubiquitin‐dependent proteolytic pathways , 1996, International journal of cancer.
[51] T. Partridge,et al. Culturing satellite cells from living single muscle fiber explants , 1995, In Vitro Cellular & Developmental Biology - Animal.
[52] M. Miyata,et al. Characterization of Mice Bearing Subclones of Colon 26 Adenocarcinoma Disqualifies Interleukin‐6 as the Sole Inducer of Cachexia , 1994, Japanese journal of cancer research : Gann.
[53] M. Burt,et al. Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin. , 1993, Cancer research.
[54] H. Ishitsuka,et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. , 1990, Cancer research.
[55] L. Moldawer,et al. Anticachectin/tumor necrosis factor‐α antibodies attenuate development of cachexia in tumor models , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[56] N. Sato,et al. Characterization of tumorigenicity, mortality, metastasis, and splenomegaly of two cultured murine colon lines. , 1981, Cancer research.
[57] F. Hirsch,et al. Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. , 1980, Cancer research.
[58] H. Kobayashi,et al. Leukemoid reaction in BALB/c mice bearing primary tumors induced by 3-methylcholanthrene. , 1978, Cancer research.
[59] F. Schabel,et al. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. , 1975, Cancer research.
[60] S. Schastak,et al. Initiation of apoptosis by photodynamic therapy using a novel positively charged and water-soluble near infra-red photosensitizer and white light irradiation. , 2008, Methods and findings in experimental and clinical pharmacology.
[61] S. Adamo,et al. Highlights on Cachexia, from the 4th Cachexia Conference, Tampa (FL), 6-9 Dec 2007 , 2008 .
[62] M. Molinaro,et al. Tumor necrosis factor-alpha gene transfer induces cachexia and inhibits muscle regeneration. , 2005, Genesis.
[63] M. Latorre,et al. ORIGINAL ARTICLES: Primary Malignant Epithelial Tumors of the Liver in Children: A Study of DNA Content and Oncogene Expression , 1998 .
[64] D. Kiang,et al. Reversal of myelofibrosis in advanced breast cancer. , 1978, The American journal of medicine.